<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Increased activation of the renin-angiotensin system (<z:mp ids='MP_0011356'>RAS</z:mp>) has been related to <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">cardiovascular disease</z:e> and type 2 <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Most randomized clinical trials have demonstrated that <z:mp ids='MP_0011356'>RAS</z:mp> blockade reduces the incidence of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, which has been explained by improved insulin secretion and insulin sensitivity </plain></SENT>
<SENT sid="2" pm="."><plain>In this review, an overview of the mechanisms that may underlie the association between the <z:mp ids='MP_0011356'>RAS</z:mp> and type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> will be provided, with focus on skeletal muscle and adipose tissue function </plain></SENT>
<SENT sid="3" pm="."><plain>This will include discussion of several human studies performed in our laboratory to investigate the metabolic and hemodynamic effects of the <z:mp ids='MP_0011356'>RAS</z:mp>, combining in vivo measurements of whole-body and tissue metabolism with molecular and immunohistochemical approaches </plain></SENT>
<SENT sid="4" pm="."><plain>Available data suggest that the detrimental effects of the <z:mp ids='MP_0011356'>RAS</z:mp> on insulin secretion are mediated by a reduction in pancreatic blood flow and induction of islet <z:mp ids='MP_0003045'>fibrosis</z:mp>, <z:mp ids='MP_0003674'>oxidative stress</z:mp> as well as <z:mp ids='MP_0001845'>inflammation</z:mp>, whereas both impaired skeletal muscle function and adipose tissue dysfunction may underlie <z:mp ids='MP_0011356'>RAS</z:mp>-induced <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>Thus, although future studies in humans are warranted, current evidence supports that targeting the <z:mp ids='MP_0011356'>RAS</z:mp> in intervention studies may improve metabolic and cardiovascular function in conditions of <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> like <z:hpo ids='HP_0001513'>obesity</z:hpo> and type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="6" pm="."><plain>Copyright Â© 2012 S </plain></SENT>
<SENT sid="7" pm="."><plain>Karger GmbH, Freiburg </plain></SENT>
</text></document>